avengebio.com Open in urlscan Pro
130.211.162.83  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Toggle navigation
 * About
 * Technology
 * Pipeline
 * Leadership
 * 
 * News
 * Investors
 * Careers
 * Contact


DEVELOPING
CELL GENERATED
IMMUNOTHERAPIES
TO ERADICATE
SOLID TUMORS

Learn More


ABOUT

AVENGE BIO WAS FOUNDED BY AN EXPERIENCED TEAM OF PROVEN BIOTECH EXECUTIVES TO
DEVELOP TRANSFORMATIVE THERAPEUTICS WHICH CAN POTENTIALLY ERADICATE INTRACTABLE
SOLID TUMORS.

Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for
precision delivery of cytokines and other highly potent immunomodulatory
molecules for a controlled period of time. Through this approach we are able to
generate robust, local and systemic anti-tumor immune responses, without the
toxicities associated with traditional immunotherapies.

The LOCOcyteTM platform was developed from extensive research and experience of
Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM
Capital, Perceptive Xontogeny, Rock Springs and other leading healthcare
investors. Together we are using the strength and efficiency of our platform to
create a broad pipeline of therapeutics that target a wide range of difficult to
treat solid tumors.


TECHNOLOGY

OUR LOCOCYTETM ALLOGENEIC CELL-BASED IMMUNOTHERAPY PLATFORM ENABLES POTENT
LOCALIZED MODULATION OF THE IMMUNE SYSTEM WHICH ALSO PRECIPITATES A SYSTEMIC
IMMUNE RESPONSE, ALLOWING US TO TREAT PREVIOUSLY INTRACTABLE CANCERS.




PIPELINE




LEADERSHIP

   
 * Management
 * Board of Directors
 * Scientific & Clinical Advisors

MICHAEL HEFFERNAN
FOUNDER & CHIEF EXECUTIVE OFFICER

MICHAEL HEFFERNAN
FOUNDER & CHIEF EXECUTIVE OFFICER

Michael Heffernan is a successful biopharmaceutical entrepreneur with over 30
years of experience in building and leading development stage and commercial
companies. He is a co-founder and CEO of Avenge Bio, Inc. He is also the Founder
and Chairman of Collegium Pharmaceutical (COLL), that is focused on developing
and commercializing products for the treatment of pain and related disorders. He
served as Collegium’s President and CEO from company’s inception until June
2018.

Mr. Heffernan is an advisor, investor and board member in numerous public and
private biotech companies. Mr. Heffernan has also held previous positions as CEO
of Onset Dermatologics, a commercial stage dermatology company that he founded
and spun out of Collegium to create PreCision Dermatology (acquired by Valeant).
He was co-founder and CEO of Clinical Studies Ltd., a pharmaceutical contract
research organization (acquired by PhyMatrix Corp). Mr. Heffernan began his
career at Eli Lilly and Company and served in numerous sales and marketing
roles.

Mr. Heffernan was named E&Y Entrepreneur of the Year, Northeast Regional Winner
in 2016. He is a registered pharmacist and earned his B.S. Degree in Pharmacy
from the University of Connecticut.

DOUG CARLSON
CHIEF OPERATING AND FINANCIAL OFFICER

DOUG CARLSON
CHIEF OPERATING AND FINANCIAL OFFICER

Doug Carlson brings over 20 years of experience with a multi-disciplinary
background in corporate finance, venture capital, M&A, business development and
commercial operations with both large and emerging growth healthcare companies.

Most recently he was the Chief Operating Officer, Chief Financial Officer and
Chief Compliance Officer of Ikena Oncology, Inc. (NASDAQ: IKNA). At Ikena, he
raised over $260M in private and public capital, led the company’s Initial
Public Offering (IPO) in March 2021, and built a robust infrastructure to hire
and integrate over 50 new employees.

Mr. Carlson previously worked at Collegium Pharmaceutical (NASDAQ: COLL) and
held numerous roles as Vice President, Commercial Operations and Vice President
Corporate Strategy & Business Development from 2013 to 2019. At Collegium, he
was a member of the management team that led its transformation from a private,
clinical stage company with approximately 15 employees to a publicly traded,
commercial business with over 300 employees.

Prior to joining Collegium, Mr. Carlson was Senior Director of Business
Development at BTG International, Inc. (LSE: BTG) where he was responsible for
global specialty pharmaceutical M&A and licensing. Prior to BTG, Mr. Carlson was
Senior Director and Head of U.S. Business Development for Lundbeck A/S (LUN:
Copenhagen). Mr. Carlson was Director of Corporate Development and M&A at
Ovation Pharmaceuticals, Inc., where he played an integral role in the sale of
Ovation to Lundbeck in 2009. Prior to Ovation, Mr. Carlson was an Associate in
the healthcare group at Pequot Ventures, the venture capital arm of Pequot
Capital Management, Inc. Mr. Carlson started his career in the healthcare
investing banking group of Cowen & Co. He holds a Bachelor of Arts degree from
Trinity College in Hartford, Conn.

CLAUDIO DANSKY ULLMANN
CHIEF MEDICAL OFFICER

CLAUDIO DANSKY ULLMANN
CHIEF MEDICAL OFFICER

Claudio Dansky Ullmann, M.D., brings more than 30 years of experience in early
and late-stage oncology therapeutics drug development, both solid tumors and
hematologic malignancies, in pharmaceutical, biotechnology, government, and
academic settings. As a member of executive leadership teams, he oversaw
clinical development, operations, and regulatory activities, and helped shape
corporate strategy, directly involved in business development activities as well
as investor and analyst interactions. Dr. Dansky Ullmann was most recently the
Chief Medical Officer at MaxCyte, responsible for the development of CARMA™ cell
therapy program. Previously, he was the Senior Vice President, Head of Clinical
Development at Infinity Pharmaceuticals, where he led the development of
Copiktra until FDA approval, and of eganelisib through first in human studies.
Earlier, he was Senior Medical Director, Global Clinical Lead in the Oncology
Therapy Area Unit at Takeda Pharmaceuticals. Before, Dr. Dansky Ullmann worked
at the Cancer Therapy Evaluation Program, National Cancer Institute, as a Senior
Investigator involved in the strategic development of novel agents and
therapeutic modalities, including numerous phase 1-3 clinical trials. He was
also involved in the development of immunotherapies at Biomira, Inc. and held
research fellowship positions in tumor immunotherapy and drug resistance at the
NCI. Dr. Dansky Ullmann is a native of Argentina and earned his M.D. at the
School of Medicine, Universidad de Buenos Aires. He completed his medical
oncology training at Guemes Private Hospital, Buenos Aires.

MANISH JAIN
SENIOR VICE PRESIDENT OF TECHNICAL OPERATIONS

MANISH JAIN
SENIOR VICE PRESIDENT OF TECHNICAL OPERATIONS

Manish Jain has more than twenty years of experience ranging from small biotech
to well established global biopharma demonstrating leadership in CMC
development, technical operations, and supply chain of early phase to commercial
biopharmaceuticals.

Most recently, Manish was the Vice President of Pharmaceutical Sciences and
Manufacturing at Genocea, where he led Process Development, Analytical
Development, External Manufacturing, and Supply Chain functions for the
portfolio of neoantigen based personalized T-cell therapy and cancer vaccine.
Prior to Genocea, Manish worked at several small and big biotechs including
Momenta Pharmaceuticals, ImmunoGen, Amgen, and Human Genome Sciences in a
variety of technical leadership roles developing multiple clinical and
commercial drug products. Manish has expertise in early phase as well as late
phase process and analytical development, technology transfer, scale up and
scale out, manufacturing operations, and supply chain of biopharmaceuticals.

Manish holds a B. Tech. in Chemical Engineering from the Indian Institute of
Technology, Bombay and an M.S. in Chemical Engineering from the University of
Virginia.

RYAN NEWMAN
VP OF OPERATIONS

RYAN NEWMAN
VP OF OPERATIONS

As VP of Operations at Avenge Bio, Inc., Ryan Newman is responsible for leading
cross-functional teams to drive the development of IND-enabling programs,
including lead candidate AVB-001. Prior to joining Avenge Bio, Inc. in 2020,
Ryan held a number of roles across Business Development and Project Management
with a focus in oncology and cell therapy. Most recently, Ryan was responsible
for operational management and organization of novel cell therapy programs at
Sigilon Therapeutics where he led integrated project teams to deliver on key
milestones from proof of concept program data through regulatory submissions and
approvals (US and ex-US). Ryan is a graduate of the University of North Carolina
at Chapel Hill, where he majored in Biology with a minor in Chemistry. He went
on to earn a M.B.A. with a focus in Project Management from the Keller School of
Management.

MICHAEL HEFFERNAN
FOUNDER & CHIEF EXECUTIVE OFFICER

MICHAEL HEFFERNAN
FOUNDER & CHIEF EXECUTIVE OFFICER

Michael Heffernan is a successful biopharmaceutical entrepreneur with over 30
years of experience in building and leading development stage and commercial
companies. He is a co-founder and CEO of Avenge Bio, Inc. He is also the Founder
and Chairman of Collegium Pharmaceutical (COLL), that is focused on developing
and commercializing products for the treatment of pain and related disorders. He
served as Collegium’s President and CEO from company’s inception until June
2018.

Mr. Heffernan is an advisor, investor and board member in numerous public and
private biotech companies. Mr. Heffernan has also held previous positions as CEO
of Onset Dermatologics, a commercial stage dermatology company that he founded
and spun out of Collegium to create PreCision Dermatology (acquired by Valeant).
He was co-founder and CEO of Clinical Studies Ltd., a pharmaceutical contract
research organization (acquired by PhyMatrix Corp). Mr. Heffernan began his
career at Eli Lilly and Company and served in numerous sales and marketing
roles.

Mr. Heffernan was named E&Y Entrepreneur of the Year, Northeast Regional Winner
in 2016. He is a registered pharmacist and earned his B.S. Degree in Pharmacy
from the University of Connecticut.

SCOTT MORENSTEIN
DIRECTOR

SCOTT MORENSTEIN
DIRECTOR

Scott Morenstein serves as Managing Director of CAM Capital, where he leads
healthcare investing. CAM Capital was established in 2012 by Bruce Kovner
following his retirement from Caxton Associates, the macro hedge fund he founded
and managed from 1983 to 2011. Prior to joining CAM Capital in 2013, Mr.
Morenstein served as Managing Director at Valence Life Sciences and before that
Principal at Caxton Advantage Venture Partners, which he joined in 2007. Prior
to joining Caxton Advantage, Mr. Morenstein served as an investment banking
associate and founding member of Seaview Securities. Mr. Morenstein began his
career at Lehman Brothers as a healthcare investment banker and equity research
analyst. Mr. Morenstein has more than 15 years experience in biopharmaceutical
investing, equity research and investment banking. Mr. Morenstein led CAM’s
investment in and served as a director of Celator Pharmaceuticals until its
acquisition by Jazz Pharmaceuticals in July 2016. He was nominated a director of
Synta Pharmaceuticals to advise the company as it explored strategic
alternatives ultimately leading to a merger with Madrigal Pharmaceuticals. He
served as a member of Gemin X’s board of directors until its acquisition by
Cephalon. He currently serves as a director of Molecular Templates (Nasdaq:
MTEM).

PAUL WOTTON, PHD
FOUNDER & DIRECTOR

PAUL WOTTON, PHD
FOUNDER & DIRECTOR

Dr. Paul K. Wotton is a co-founder and Director at Avenge Bio, bringing
significant experience spanning scientific research, product development and
corporate growth gained over a thirty-year career. In addition, he serves as CEO
of Obsidian Therapeutics. Dr. Wotton previously served as the Founding President
and CEO of Sigilon Therapeutics, Inc. Prior to Sigilon, Dr. Wotton served as
President and Chief Executive Officer of Ocata Therapeutics until its
acquisition by Astellas Pharma where he was also Co-Chairman of the Office of
Integration. In previous roles, he served as President and Chief Executive
Officer of Antares Pharma (NASDAQ:ATRS) as well as Chief Executive Officer of
Topigen Pharmaceuticals. Dr. Wotton is a named inventor on numerous patents and
was the Ernst & Young Entrepreneur of the Year Regional (NJ) Winner Life
Sciences in 2014. He currently serves on the Boards of Directors of Vericel
Corporation (NASDAQ: VCEL), and Cynata Therapeutics (ASX: CYP) as its Chairman,
and previously served on the Board of Veloxis Pharmaceuticals A/S prior to its
sale to Asahi Kasei.

BEN ASKEW, PHD
DIRECTOR

BEN ASKEW, PHD
DIRECTOR

Ben Askew serves as a Partner at the Perceptive Xontogeny Venture Fund where he
provides and scientific leadership and guidance for preclinical and
clinical-stage companies seeded and incubated at Xontogeny.

Ben contributed to the discovery of a number of approved drugs and several
additional candidates currently in late-stage clinical trials as a result of his
leadership roles in research and early development at Merck (1990-2000), Amgen
(2000-2005), and Merck Serono (2005-2011).  In 2011, Ben joined Third Rock
Ventures, as entrepreneur-in-residence where he provided strategic input and
scientific leadership for several of Third Rock’s portfolio companies, most
notably Sage Therapeutics and Blueprint Medicines.  Ben joined SciFluor Life
Sciences in 2013 as Vice President of Research, where he has led the expansion
SciFluor’s pipeline and advanced two compounds into clinical development.

Ben’s academic training began at Gannon University, where he graduated cum-laude
with Bachelor of Science degrees in chemistry and biology. He went on to the
University of Pittsburgh, where he obtained a Ph.D. in Organic Chemistry. Ben
serves on Scientific Advisory Boards for several Boston-area companies.

DAVID E. MOLLER, MD
SCIENTIFIC ADVISOR

DAVID E. MOLLER, MD
SCIENTIFIC ADVISOR

Dr. David Moller has extensive experience in biopharmaceutical R&D across a
range of therapeutic areas and modalities. He currently serves as Chief
Scientific Officer at Poxel SA, a clinical stage biotechnology company pursuing
novel therapies for rare metabolic diseases. David also led R&D efforts as CSO
at Sigilon Therapeutics; this technology employs immune-privileged engineered
cell implants for the treatment of chronic diseases – including hemophilia and
lysosomal storage diseases.  

David’s past experience includes 20 years leading R&D efforts at Merck and Eli
Lilly. While Vice President, Metabolic Disorders at Merck, David’s team
discovered and delivered several key additions to the pipeline – including
sitagliptin (JanuviaTM). As Vice President Endocrine-Cardiovascular and Clinical
Investigation at Lilly, David’s team delivered numerous additions to the
pipeline including: dulaglutide (TrulicityTM), novel insulins, dual incretin
agonists (tirzepatide), and several Phase II-III molecules targeting
musculoskeletal, urologic and cardiorenal disorders. While leading global
discovery and develop efforts in these areas, David had additional
responsibility for scientific assessments of BD projects and execution of
partnerships involving clinical stage programs, preclinical projects and
technology platforms. At Eli Lilly, David also served as Vice President,
Business Development – in this role, he established and led the Emerging
Technology and Innovation team; a Boston based effort focusing on access to
early phase external innovation across all disease areas including oncology and
novel platforms – plus establishing and leveraging flexible funding models and
venture capital partnerships. David has also held additional recent roles
including as SAB member at Axcella Health and as strategic advisor to TVM
Capital.  

David received a B.S. from Brown University and an M.D. from University of
Cincinnati. He completed clinical and research training programs at George
Washington University and Harvard. David also served on the Harvard faculty for
several years where his laboratory discovered important clues to the molecular
pathogenesis of metabolic disorders. David has published more than 130
peer-reviewed papers; his honors include election to the American Society of
Clinical Investigation, the Association of American Physicians, and appointment
as an adjunct professor at the Karolinska Institute.

KATY REZVANI, MD, PHD
SCIENTIFIC ADVISOR

KATY REZVANI, MD, PHD
SCIENTIFIC ADVISOR

Katy Rezvani M.D, PhD is the Sally Cooper Murray Chair in Cancer Research,
Professor of Medicine, Chief of Section for Cellular Therapy, Director of
Translational Research and Director of the GMP Facility at MD Anderson Cancer
Center. She also serves as the Executive Director of the Adoptive Cell Therapy
Platform at MD Anderson. Her research laboratory focuses on the role of natural
killer (NK) cells in mediating immunity against hematologic and solid tumors.
The goal of this research is to understand mechanisms of tumor-induced NK cell
dysfunction and to develop strategies to genetically engineer NK cells in order
to enhance their in vivo anti-tumor activity and persistence. Findings from Dr.
Rezvani’s lab have led to the approval and funding of several
investigator-initiated clinical trials of NK cell immunotherapy in patients with
hematologic malignancies and solid tumors, as well as the first-in-human
clinical trial of off-the-shelf CAR-transduced cord blood NK cells in patients
with relapsed/refractory lymphoid malignancies. Dr. Rezvani’s work is supported
by multiple grants from the National Cancer Institute, the Leukemia and Lymphoma
Society, the American Cancer Society, Stand Up to Cancer and the Cancer
Prevention & Research Institute of Texas (CPRIT). Dr. Rezvani completed her
medical training at University College London, followed by Fellowships of the
Royal College of Physicians and the Royal College of Pathologists of the United
Kingdom, a Ph.D. in Immunology from Imperial College London and postdoctoral
studies at the National Institutes of Health.

OMID VEISEH, PHD
FOUNDER AND CHAIRMAN OF THE SCIENTIFIC ADVISORY BOARD

OMID VEISEH, PHD
FOUNDER AND CHAIRMAN OF THE SCIENTIFIC ADVISORY BOARD

Dr. Omid Veiseh is a Co-Founder of Avenge Bio and an Assistant Professor and
CPRIT Scholar in Cancer Research in the Department of Bioengineering at Rice
University. He received a dual Ph.D. in Materials Science & Engineering and
Nanotechnology from the University of Washington. Dr. Veiseh completed his
postdoctoral research with Prof. Robert Langer and Prof. Daniel Anderson at MIT
and Harvard Medical School. Over the course of his career he has authored, or
co-authored more than 50 peer-reviewed publications including those in Nature,
Nature Biotechnology, Nature Materials, Nature Medicine, and is an inventor on
20 pending or awarded patents, many of which have been licensed for
commercialization by 3 separate biotechnology companies. He is Co-Founder of
Sigilon Therapeutics. Throughout his career he has received numerous awards and
fellowships including: a $2 million CPRIT Scholar In Cancer Research Award from
the state of Texas, and was named one of MedTech Boston’s 40 Under 40 Healthcare
Innovators for 2017.

AMIR ANTHONY JAZAERI, MD
SCIENTIFIC ADVISOR

AMIR ANTHONY JAZAERI, MD
SCIENTIFIC ADVISOR

Dr. Jazaeri is a Professor and the Vice Chair for Clinical Research in the
Department of Gynecologic Oncology and Reproductive Medicine at the University
of Texas MD Anderson Cancer Center.  As the Director for the Gynecologic Cancer
Immunotherapy Program, he has helped establish a broad base immune-oncology
program for gynecologic cancers that include adoptive cell
therapies, intraperitoneal immunotherapies, and translational immunobiology. His
other areas of research interest include innovative clinical trial designs and
identification of novel immunotherapy targets for gynecologic cancers.

JOSÉ OBERHOLZER, MD, MHCM, FACS
SCIENTIFIC ADVISOR

JOSÉ OBERHOLZER, MD, MHCM, FACS
SCIENTIFIC ADVISOR

José Oberholzer, M.D., is a physician-scientist with a long track record in cell
therapy. Dr. Oberholzer, brings a wealth of highly valuable cell encapsulation
expertise to AvengeBio’s Scientific Advisory Board. He is an endowed Professor
of Surgery, Experimental Pathology and Biomedical Engineering, and the director
of the Charles O. Strickler Transplant Center at the University of Virginia.
Previous to that he was a Professor of Surgery and Bioengineering, and Chief of
the Division of Transplantation at the University of Illinois at Chicago (UIC).
Dr. Oberholzer graduated from the University of Zurich Medical School in
Switzerland and obtained a master’s in health care management from Harvard
University. He completed his surgical training at the University of Geneva
(Switzerland), as well as at the University of Alberta in Edmonton (Canada),
where he completed a fellowship in hepatobiliary and pancreatic surgery and
transplantation.

RAHUL ANIL SHETH, MD
SCIENTIFIC ADVISOR

RAHUL ANIL SHETH, MD
SCIENTIFIC ADVISOR

Dr. Rahul Sheth is an Assistant Professor in the Department of Interventional
Radiology at MD Anderson. Dr. Sheth received his undergraduate degree in
Chemistry and Physics at Harvard University and his MD degree through the Health
Sciences and Technology program at Harvard Medical School.  After a medicine
internship at the University of Pittsburgh, Dr. Sheth returned to Boston and
completed his residency training in diagnostic radiology as well as fellowship
training in Interventional Radiology at Massachusetts General Hospital. As a
clinician-scientist, Dr. Sheth studies how locoregional therapies can have
positive systemic ramifications for cancer patients. His research interests
include optical molecular imaging, tumor microenvironmental factors affecting
minimally invasive cancer therapies, photothermal ablation, and cancer
immunology.

ULRICH VON ANDRIAN, MD
SCIENTIFIC ADVISOR

ULRICH VON ANDRIAN, MD
SCIENTIFIC ADVISOR

Mallinckrodt Professor of Immunopathology at Harvard Medical School

Program Leader, Basic Immunology at Ragon Institute of MGH, MIT and Harvard

Director, HMS Center for Immune Imaging

Dr. Ulrich H. von Andrian, “Uli”, received his medical degree from the
Ludwig-Maximilians University in Munich, Germany, where he also conducted
doctorate research on blood-brain barrier dysfunction following brain injury. 
In 1989, he joined the La Jolla Institute for Experimental Medicine and UCSD as
a postdoctoral fellow working with Dr. Karl-E. Arfors.  His postdoctoral
research involved the development of intravital microscopy techniques that led
to the discovery of the multi-step leukocyte adhesion cascade in vivo.  After a
second postdoctoral fellowship in the laboratory of Dr. Eugene C. Butcher at
Stanford University, Dr. von Andrian joined the Faculty of Harvard Medical
School in 1994. He was appointed to his current position in 2006. His scientific
research is focused on the regulation and function of immune cells in health and
disease. To this end, his laboratory employs intravital microscopy techniques
combined with other experimental approaches to study the migration,
communication, differentiation and function of immune cells in living animals.

NATHAN RETICKER-FLYNN
SCIENTIFIC ADVISOR

NATHAN RETICKER-FLYNN
SCIENTIFIC ADVISOR

Nathan Reticker-Flynn is a Biomedical Engineer and tumor immunologist working at
the interfaces of cancer metastasis, tumor evolution, adaptive immunity, and
immuno-oncology. He received his PhD from the Massachusetts Institute of
Technology while working with Dr. Sangeeta Bhatia as part of the Harvard-MIT
Division of Health Sciences and Technology. His doctoral studies focused upon
developing technologies for interrogating interactions between tumors and
extracellular matrix during metastatic progression. Dr. Reticker-Flynn performed
his postdoctoral studies in the laboratory of Dr. Edgar Engleman at Stanford
University School of Medicine. There, his work has focused on using systems
approaches and mouse models to investigate tumor-immune interactions during
metastasis and responses to immunotherapies. His discoveries include the
revelation that effective immunotherapies require systemic activation of
anti-tumor immunity and that lymph node metastases serve to reeducate adaptive
immune responses in a manner that promotes distant metastasis. He currently
focuses on using systems approaches and mouse models to elucidate the mechanisms
of tumor-immune tolerance during metastatic progression and to develop novel
immunotherapies to treat patients with metastatic disease.

IN THE NEWS

APR 7, 2022

Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors –
National Cancer Institute

Learn More

PRESS RELEASES

AUG 22, 2022

Avenge Bio Announces Peer-Reviewed Publication on Preclinical Proof-of-Concept
for LOCOcyte™ Platform Technology in Malignant Mesothelioma

Learn More

AUG 3, 2022

Avenge Bio Announces FDA Clearance of the AVB-001 IND for the Treatment of
Ovarian Cancer, a Novel Cellular Therapy Leveraging the LOCOcyte™ Immunotherapy
Platform

Learn More

MAY 20, 2022

Avenge Bio Presents Preclinical Data at the American Society of Gene & Cell
Therapy (ASGCT) Annual Meeting

Learn More

MAR 28, 2022

Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer

Learn More

MAR 2, 2022

Avenge Bio Announces Peer-Reviewed Publication on Preclinical Proof of Concept
for LOCOcyte™ Platform Technology

Learn More

FEB 22, 2022

Avenge Bio Appoints Douglas Carlson as Chief Operating and Financial Officer

Learn More

JAN 5, 2022

Avenge Bio Announces Closing of $45 Million Series A Financing

Learn More

PRESENTATIONS AND PUBLICATIONS

MAY 4, 2022

Evaluation of Implantable Cytokine Factories for Eradication of Malignant
Pleural Mesothelioma (MPM) Tumors in Mice with Safe and Predictable Dosing in
Non-human Primates

Learn More

MAY 4, 2022

IL-12-Based Cytokine Factories Modulate Tumor Microenvironment to Eradicate
Pancreatic Tumors in Mice and are Well Tolerated in Non-human Primates

Learn More

MAR 3, 2022

Clinically translatable cytokine delivery platform for eradication of
intraperitoneal tumors

Learn More

DEC 1, 2021

Tumor Adjacent Cytokine Factories for Eradication of Ovarian Cancer Tumor Burden
in Mice Through Cytotoxic T-cell Activation with Safe and Predictable Dosing in
Non-human Primates

Learn More


INVESTORS




WANT TO WORK AT AVENGE BIO?CAREERS

General Information
info@avengebio.com

Natick
22 Strathmore Rd, STE 241
Natick, MA 01760
(508) 290-0502

Quincy
1250 Hancock Street
Suite 501s
Quincy, MA 02169

©2022 Avenge Bio